Explore

Innovations

                                        
                                    Published
                            
                Healthcare & Pharmaceuticals
            
Modulators of Class IIa HDACs
                UQ has exploited structural differences between Class I and IIa HDACs to develop two generations of new compounds that are potent and selective inhibitors of class IIa HDACs.
            
By
                            The University of Queensland
                        
Reference Number  
                08993
            
Last Update  
                 May 27, 2022
            
                                    Published
                            
                Medical
            
Selective AAK1 inhibitors
                Researchers at Stanford have developed kinase inhibitors that could be used as broad-spectrum antiviral therapeutics to treat emerging viruses, such as Dengue, Chikungunya, Ebola.
            
By
                            Stanford University
                        
Reference Number  
                03193
            
Last Update  
                 Nov 15, 2021
            
        Do you have an innovative technology, product or service?Add your solution to the world’s most advanced open innovation platform and get seen by global corporations seeking new solutions – all free of charge.

View all

Gain innovation insights and shape the future with LEO. Sign up for our newsletter today!